151 related articles for article (PubMed ID: 36179946)
1. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
Castillo-Regalado E; Ríos R; Aràjol C; Gely C; Márquez L; Calafat M; González-Muñoza C; Cañete F; Mesonero F; Guardiola J; Garcia-Planella E; Mañosa M; Domènech E
Gastroenterol Hepatol; 2023 Mar; 46(3):164-170. PubMed ID: 36179946
[TBL] [Abstract][Full Text] [Related]
2. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
Gjuladin-Hellon T; Gordon M; Iheozor-Ejiofor Z; Akobeng AK
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008414. PubMed ID: 31220875
[TBL] [Abstract][Full Text] [Related]
3. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
4. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.
Schoepfer AM; Bortolotti M; Pittet V; Mottet C; Gonvers JJ; Reich O; Fournier N; Vader JP; Burnand B; Michetti P; Froehlich F
Aliment Pharmacol Ther; 2014 Oct; 40(8):930-7. PubMed ID: 25146487
[TBL] [Abstract][Full Text] [Related]
5. 5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study.
Duricova D; Pedersen N; Elkjaer M; Jensen JK; Munkholm P
J Crohns Colitis; 2010 Nov; 4(5):575-81. PubMed ID: 21122562
[TBL] [Abstract][Full Text] [Related]
6. [Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study].
Domènech E; Scala L; Bernal I; García-Planella E; Casalots A; Piñol M; Esteve-Comas M; Cabré E; Boix J; Gassull MA
Gastroenterol Hepatol; 2004 Dec; 27(10):563-7. PubMed ID: 15574279
[TBL] [Abstract][Full Text] [Related]
7. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
[TBL] [Abstract][Full Text] [Related]
8. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
Picetti D; Kim J; Zhu W; Sandborn WJ; Jairath V; Singh S
Dig Dis Sci; 2022 Jul; 67(7):3115-3123. PubMed ID: 34797442
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting.
Allocca M; Landi R; Bonovas S; Fiorino G; Papa A; Spinelli A; Furfaro F; Peyrin-Biroulet L; Armuzzi A; Danese S
Digestion; 2017; 96(3):166-172. PubMed ID: 28903094
[TBL] [Abstract][Full Text] [Related]
10. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Naidoo K; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2011 Jan; (1):CD008414. PubMed ID: 21249709
[TBL] [Abstract][Full Text] [Related]
11. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
12. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
13. Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases.
Merra G; Gasbarrini G; Laterza L; Pizzoferrato M; Poscia A; Scaldaferri F; Arena V; Fiore F; Cittadini A; Sgambato A; Franceschi F; Gasbarrini A
World J Gastroenterol; 2012 Sep; 18(36):5065-71. PubMed ID: 23049215
[TBL] [Abstract][Full Text] [Related]
14. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
Candia R; Bravo-Soto GA; Monrroy H; Hernandez C; Nguyen GC
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012328. PubMed ID: 32746500
[TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Florent C; Cortot A; Quandale P; Sahmound T; Modigliani R; Sarfaty E; Valleur P; Dupas JL; Daurat M; Faucheron JL; Lerebours E; Michot F; Belaiche J; Jacquet N; Soulé JC; Rothman N; Gendre JP; Malafosse M
Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
[TBL] [Abstract][Full Text] [Related]
16. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for maintenance of remission in Crohn's disease.
Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
[TBL] [Abstract][Full Text] [Related]
18. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
19. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.
Bodini G; Giannini EG; De Maria C; Dulbecco P; Furnari M; Marabotto E; Savarino V; Savarino E
Dig Liver Dis; 2017 Feb; 49(2):175-180. PubMed ID: 27864028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
